title: Mantle cell lymphoma: a retrospective study on 27 patients. Clinical features and natural history.
abstract: OBJECTIVE
  Mantle cell lymphoma (MCL) is a separate histological and clinical entity recently recognized in the new revised European-American Lymphoma Classification. Little information exists regarding its therapy. We report the results of a retrospective study of 27 patients affected by MCL evaluating the clinical characteristics and the results of different therapeutical options used during the period of observation.
  
  
  METHODS
  From 1983 to 1993, we observed 27 patients affected by MCL according to the criteria proposed by European Lymphoma Task Force in a revision of 55 cases classified as NHL E according to Working Formulation (WF) criteria. We analyzed the clinical characteristics, the prognostic factors and the O.S. of these patients.
  
  
  RESULTS
  The clinical characteristics of our patients (pts) are similar to those observed in other series: male prevalence, median age 62 years, B symptoms in 9 cases, P.S. > 2 in 11 cases, 3 pts were in stage I and II, 4 in stage III, 20 in stage IV; 18 pts had a bone marrow involvement, 13 pts had spleen enlargement and 14 had extranodal localization; 8 pts had bulky tumor and 5 had LDH above normal. The CR rate was 51.8%, the median O.S. was 43 months, and DFS was 18 months; the pts without bulky disease and with localized disease had a better CR rate. The inclusion of an anthracycline in the regimen did not affect the results.
  
  
  CONCLUSIONS
  Our results were not divergent from those present in literature. The mantle cell lymphoma is an incurable and highly aggressive disease. Autologous bone marrow transplantation as support of high dose chemotherapy or allogenic bone marrow transplantation may be a chance for some patients, but not for the majority of patients, which are older than 65 years. Studies of a larger series and different therapeutical approaches, i.e. using biological modifiers in association or as maintenance after chemotherapy are essential.
authors.affiliation: Divisione di Ematologia, Azienda Ospedaliera S. Giovanni Battista, Torino, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Bertini
authors.forename: C
authors.initials: C
authors.lastname: Rus
authors.forename: R
authors.initials: R
authors.lastname: Freilone
authors.forename: B
authors.initials: B
authors.lastname: Botto
authors.forename: R
authors.initials: R
authors.lastname: Calvi
authors.forename: D
authors.initials: D
authors.lastname: Novero
authors.forename: L
authors.initials: L
authors.lastname: Orsucci
authors.forename: U
authors.initials: U
authors.lastname: Vitolo
authors.forename: G
authors.initials: G
authors.lastname: Palestro
authors.forename: L
authors.initials: L
authors.lastname: Resegotti
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018943:Anthracyclines / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000097:blood; D008228:Lymphoma, Non-Hodgkin / Q000175:diagnosis* / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D018943:Anthracyclines; D007770:L-Lactate Dehydrogenase